

XXXIV

**Congreso Nacional
de la Sociedad
Española de
Medicina Interna**

XXIX

**Congreso de la
Sociedad Andaluza de
Medicina Interna
(SADEMI)**

21-23

Noviembre 2013

Palacio de Ferias y
Congresos de Málaga
Málaga

Lixisenatida

Dr Javier Ena


Servicio de Medicina Interna

Hospital Marina Baixa. Alicante

Indice


- Efecto incretina
- Diferencias entre iDPP-4 y agonistas GLP-1
- Tipos de agonistas GLP-1
- Lixisenatida en DM2 de corta evolución
- Lixisenatida en DM2 de larga evolución
- Resumen

Efecto incretina




Efecto incretina en DM tipo 2


Plasma glucose concentrations during the 180 min period after meal ingestion



Increase in plasma concentrations of insulin (top) and c-peptide (bottom) for type 2 diabetic patient and healthy subjects after ingestion of a mixed breakfast meal



GLP-1 concentrations (top) and GIP concentrations (bottom) using NH₂-terminal assays



Inh. DPP4 vs. Análogos GLP-1

Inh DPP4

- Estimulación secreción insulina postprandial
- Inhibición secreción de glucagón

Análogos GLP-1

- Estimulación secreción insulina postprandial
- Inhibición secreción de glucagón
- Enlentecimiento vaciamiento gástrico




Figure 1. Mean (s.e.) postprandial plasma glucose concentration during a standard meal at baseline and after treatment with exenatide or sitagliptin. Exenatide was administered at T = -15 min. Sitagliptin was administered at T = -30 min. Standardized meal was given at T = 0 min. Adapted from

Inh. DPP4 vs. Análogos GLP-1

Inh DPP4

- Estimulación secreción insulina postprandial
- Inhibición secreción de glucagón

Ingesta calórica

+ 130 cal/d vs. - 134 cal/d

Peso

NS vs. -2-3 Kg

Descenso HbA1c

0.74 % vs. 0.9 a 1.0%

Análogos GLP-1

- Estimulación secreción insulina postprandial
- Inhibición secreción de glucagón
- Enlentecimiento vaciamiento gástrico




Figure 1. Mean (s.e.) postprandial plasma glucose concentration during a standard meal at baseline and after treatment with exenatide or sitagliptin. Exenatide was administered at T = -15 min. Sitagliptin was administered at T = -30 min. Standardized meal was given at T = 0 min. Adapted from

Agonistas GLP-1

Acción corta

Derivados de Exendina-4

- Exenatida
 - $T_{1/2} \approx 2-4$ h.
- Lixisenatida
 - $T_{1/2} \approx 2-6$ h.
 - Afinidad R x4

Acción Larga (Análogos GLP-1)

Derivados de GLP-1 humano


- Liraglutida
 - $T_{1/2} \approx 13$ h.
- Exenatida LAR
 - $T_{1/2} \approx 2$ sem.
- Albiglutida
- Dulaglutida
- Taspoglutida

Análogos GLP-1


Acción corta

Derivados de Exendina-4
EFECTO PRANDIAL
Exenatida, Lixisenatida

Efecto sobre la
GPA




Efecto sobre la
GPP




Acción larga

Derivados de GLP-1
EFECTO BASAL
Liraglutida, Exenatida LAR, Albiglutida

Efecto sobre la
GPA



Efecto sobre la
GPP



Contribución GBA y GPP sobre HbA1c





Figure 3—Relative contributions of post-prandial (□) and fasting (■) hyperglycemia (%) to the overall diurnal hyperglycemia over quintiles of HbA_{1c}. a, significant difference was observed between fasting and post-prandial plasma glucose (paired t test); b, significantly different from all other quintiles (ANOVA); c, significantly different from quintile 5 (ANOVA).

Algoritmo Tratamiento Diabetes Mellitus Tipo 2



Lixisenatida



Diabetes Mellitus tipo 2 (corta evolución)

Table 1—Demographic and baseline characteristics (safety population)

Demographic variable	Lixisenatide morning injection (n = 255)	Lixisenatide evening injection (n = 255)	Combined placebo (n = 170)
Sex (male/female), %	38.4/61.6	44.7/55.3	47.6/52.4
Race (Caucasian/Black/Asian/other), %	86.7/2.7/8.6/2.0	89.4/2.4/7.8/0.4	91.2/2.4/6.5/0
Age, years	54.5 ± 9.2	54.8 ± 10.4	55.0 ± 9.4
Duration of diabetes, years	6.2 ± 5.3	6.2 ± 5.4	5.9 ± 4.7
Weight, kg	90.1 ± 21.0	89.0 ± 20.7	90.4 ± 20.1
BMI, kg/m ²	33.2 ± 6.9	32.5 ± 5.8	33.1 ± 6.5
HbA _{1c} , %	8.0 ± 0.9	8.1 ± 0.9	8.1 ± 0.9
HbA _{1c} , mmol/mol	64 ± 9.8	65 ± 9.8	65 ± 9.8
FPG, mmol/L	9.4 ± 2.2	9.3 ± 2.3	9.5 ± 2.3
Duration of metformin use, years	3.7 ± 3.3	3.7 ± 3.9	3.3 ± 3.5
Daily metformin dose, mg	1,969 ± 447	1,943 ± 406	2,001 ± 440

Data are presented as mean ± SD unless otherwise indicated.

Efficacy and safety of lixisenatide (GetGoal-M)



Lixisenatida

DM tipo 2 (corta evolución)

Table 2—Adverse events

Type of AE	Lixisenatide morning injection (n = 255)	Lixisenatide evening injection (n = 255)	Combined placebo (n = 170)
Any AE, n (%)	177 (69.4)	177 (69.4)	102 (60.0)
Any serious AE, n (%)	5 (2.0)	8 (3.1)	2 (1.2)
Death	0	0	0
Discontinuation due to AE, n (%)	18 (7.1)	14 (5.5)	2 (1.2)
Gastrointestinal disorders (any), n (%)	93 (36.5)	105 (41.2)	44 (25.9)
Nausea, n (%)	58 (22.7)	54 (21.2)	13 (7.6)
Vomiting, n (%)	24 (9.4)	34 (13.3)	5 (2.9)
Diarrhea, n (%)	27 (10.6)	27 (10.6)	15 (8.8)
Symptomatic hypoglycemia*, n (%)	6 (2.4)	13 (5.1)	1 (0.6)
Severe hypoglycemia†	0	0	0

Lixisenatida vs. Exenatida

Estudio de No-inferioridad
El límite superior (IC 95%) de Diferencia de HbA1c se fijó en < 0.4%

Table 1—Demographic and baseline characteristics (safety population)

Demographic variable	Lixisenatide 20 µg QD (n = 318)	Exenatide 10 µg BID (n = 316)	All (n = 634)
Male/female, %	47.5/52.5	59.2/40.8	53.3/46.7
Caucasian/Black/Asian/other race, %	93.1/2.5/0.9/3.5	92.4/3.2/1.3/3.2	92.7/2.8/1.1/3.3
Age (years), mean ± SD	57.3 ± 9.2	57.6 ± 10.7	57.4 ± 9.9
Duration of diabetes (years), mean ± SD	6.8 ± 5.5	6.8 ± 4.9	6.8 ± 5.2
Weight, mean ± SD (kg)	94.0 ± 19.6	96.1 ± 22.5	95.0 ± 21.13
BMI (kg/m ²), mean ± SD	33.7 ± 6.3	33.5 ± 6.5	33.6 ± 6.4
HbA _{1c} (%), mean ± SD	8.03 ± 0.8	8.02 ± 0.8	8.02 ± 0.8
FPG, mg/dL (mean ± SD, mmol)	9.7 ± 2.0 (174.6 ± 36.0)	9.7 ± 2.3 (174.6 ± 41.4)	9.7 ± 2.1 (174.6 ± 37.8)
PAGI-QOL total score	0.59 ± 0.7	0.56 ± 0.7	0.58 ± 0.7
Daily metformin dose (mg), mean ± SD	2,020 ± 459	2,058 ± 453	2,039 ± 456

BID, twice daily; PAGI-QOL, Patient Assessment of Upper Gastrointestinal Disorders–Quality of Life; QD, once daily.

Lixisenatida vs. Exenatida




Table 2—Safety profile during the 24-week, double-blind treatment period

AE N (%)	Lixisenatide 20 µg QD (n = 318)	Exenatide 10 µg BID (n = 316)
Any AE	221 (69.5)	228 (72.2)
Any serious AE	9 (2.8)	7 (2.2)
Death	1 (0.3)	1 (0.3)
AE leading to discontinuation	33 (10.4)	41 (13.0)
Gastrointestinal disorders (any)	137 (43.1)	160 (50.6)
Preferred AE term (≥10% in either group)		
Nausea	78 (24.5)	111 (35.1)
Vomiting	32 (10.1)	42 (13.3)
Diarrhea	33 (10.4)	42 (13.3)
Symptomatic hypoglycemia	8 (2.5), 8 events	25 (7.9), 48 events
Severe hypoglycemia	0	0

BID, twice daily; QD, once daily.

CONCLUSIONS—Add-on lixisenatide once daily in type 2 diabetes inadequately controlled with metformin demonstrated noninferior improvements in HbA_{1c}, with slightly lower mean weight loss, lower incidence of hypoglycemia, and better gastrointestinal tolerability compared with exenatide twice daily.

Análogos GLP-1* + Insulina Basal

- 2 escenarios:
- **Metformina+ Análogo GLP-1 + Insulina basal**
- Metformina + Insulina basal + Análogo GLP-1

*Exenatida, Lixisenatida, Liraglutida

Revisión Sistemática Análogos GLP-1+ Insulina

Table 1 Characteristics of trials included in the systematic review

Parameter	References				
	Arnolds et al ¹⁹	Riddle et al ²⁰	Buse et al ²¹	Morrow et al ²²	Seino et al ²³
Design	R, OL, PG, SC 4 weeks n = 48	R, DB, PC, PG 24 weeks n = 34	R, DB, PC, PG, MC 30 weeks n = 259	OL, CO 36 days n = 33	R, DB, PC, PG, MC 24 weeks n = 311
Age (years)	57	55	59	50	58
Male (%)	60	NR	57	70	NR
Race, white (%)	NR	NR	78	79	0
Diabetes duration (years)	6	9	12	7	14
Body mass index (kg/m ²)	32	33	33	33	25
Baseline FPG (mmol/L)	5.3	NR	8.1	9.7	7.7
Baseline A1c (%)	8.1	7.8*	8.4	8.3	8.5
Intervention	Glargine (0.42 u/kg) + metformin + exenatide (5–10 µg BID)	Metformin + exenatide (5–10 µg BID) + glargine (0.50 u/kg)	Glargine + exenatide (10 µg BID) ± metformin and/or PIO	Liraglutide (1.8) + detamir (0.5 u/kg) ± metformin	Basal insulin ± SU + lixisenatide (20 µg QD)
Control (s)	Glargine (0.36 u/kg) + metformin + sitagliptin (100 mg QD) Glargine (0.42 u/kg) + metformin	Metformin + placebo + glargine (0.56 u/kg)	Glargine + placebo ± metformin and/or PIO	Liraglutide (1.8 mg) ± metformin Detamir (0.5 u/kg) ± metformin	Basal insulin ± SU + placebo
Sequence generation	No	No	Yes	NA	No
Concealment of allocation	No	No	No	NA	No
Blinding	No	Yes	Yes	No	Yes
Incomplete outcome data	No	No	No	No	No
Selective outcome reporting	No	No	Yes	No	No

Abbreviations: BID, twice daily; CO, crossover; DB, double blind; MC, multicenter; n, number; NR, not reported; NA, not applicable; OL, open label; PG, parallel group; PIO, pioglitazone; R, randomized; SC, single center; U, units; QD, once daily.

Análogo GLP-1+Insulina Basal

DM tipo 2 fase avanzada

	Buse et al N= 259 Met+Glar+Placebo vs. Met+Glar+Exenatida	Seino et al N= 311 SU+Insulina basal+Placebo vs SU+Insulina Basal+Lixisenatida
Reducción HbA1c (%)	-1.04% vs. - 1.74%	+0.11% vs. -0.77%
HbA1c < 7%	35% vs. 60%	5.2% vs. 35.6%
HbA1c ≤ 6.5%	12% vs. 40%	1.3% vs. 17.8%
Incremento dosis insulina	20 u/dia vs. 13 u/dia	
Reducción GBA (mg/dL)	27 vs. 29	4.5 vs. 7.5
Reducción GPP 2 h. (mg/dL)	31 vs. 32	10 vs. 140
Reducción peso (Kg)	-1.1 vs. -1.8	+0.06 vs. - 0.38
TAS y TAD (Diferencia)	-4.4 mmHg y - 3.4 mmHg	
Frecuencia cardiaca	+ 3.0 lpm	

Buse JB. Ann Intern Med. 2011;154:103 .

Seino Y. Diab Obes Metab. 2012; 14:910

Lixisenatida

Resumen

- Agonista GLP-1 pacientes con DM2 e IMC > 30 Kg/m²
- Diabetes tipo 2, corta y larga evolución
- Control de glucemia prandial
- Dosis 10 ug/d sc x 2 semanas → 20 ug/d
- Descenso HbA1c ~ 1%
- Insuficiencia renal 30-50 ml/min (datos limitados)
- Insuficiencia renal < 30 ml/min (no usar)
- Efectos adversos GI, pancreatitis, Ca medular tiroides
- No interacciones significativas